Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JON D OLSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1619966819
CMS profile
163770
Location
BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,835.24

161 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JON D OLSON

NPI 1619966819 · CMS profile ID 163770

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619966819?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JON D OLSON, NPI 1619966819, CMS profile ID 163770. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619966819?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JON D OLSON, NPI 1619966819, CMS profile ID 163770. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619966819?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JON D OLSON, NPI 1619966819, CMS profile ID 163770, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 161 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1619966819?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

161 matching records · $2,835.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 161 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 161.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $15.5505/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827840893 CMS
Novartis Pharmaceuticals Corporation $24.1605/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813130387 CMS
Avanir Pharmaceuticals, Inc. $12.5704/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801026837 CMS
GT Medical Technologies, Inc $6.0004/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840017697 CMS
Janssen Pharmaceuticals, Inc $17.3604/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788492183 CMS
Allergan, Inc. $13.8604/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792894539 CMS
AbbVie Inc. $3.7804/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427329 CMS
Novartis Pharmaceuticals Corporation $16.3304/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813130391 CMS
Biogen, Inc. $16.3704/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827840889 CMS
AbbVie Inc. $7.2604/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427323 CMS
Lilly USA, LLC $11.5304/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818578999 CMS
Lundbeck LLC $19.2304/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845926579 CMS
UCB, Inc. $19.0704/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807337451 CMS
Biohaven Pharmaceuticals, Inc. $12.3904/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852582605 CMS
Biohaven Pharmaceuticals, Inc. $4.4304/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852582607 CMS
EMD Serono, Inc. $11.1804/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849170961 CMS
UCB, Inc. $17.0804/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807335709 CMS
Allergan, Inc. $13.8304/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792894537 CMS
Amgen Inc. $18.4104/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825449075 CMS
Novartis Pharmaceuticals Corporation $10.0404/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813130383 CMS
Supernus Pharmaceuticals, Inc. $20.8304/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845091903 CMS
AbbVie Inc. $12.9204/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427317 CMS
GT Medical Technologies, Inc $14.0504/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840006373 CMS
AbbVie Inc. $5.9004/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427311 CMS
Allergan, Inc. $12.6803/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792894535 CMS
Biogen, Inc. $14.0603/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827840887 CMS
Amgen Inc. $22.2603/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825449069 CMS
Novocure Inc. $52.9103/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 823637335 CMS
ACADIA Pharmaceuticals Inc $13.7503/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838013711 CMS
UCB, Inc. $22.6503/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807322011 CMS
Teva Pharmaceuticals USA, Inc. $13.9903/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839615147 CMS
E.R. Squibb & Sons, L.L.C. $12.3303/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783517965 CMS
AbbVie Inc. $10.4803/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427303 CMS
AbbVie Inc. $13.2703/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427297 CMS
Teva Pharmaceuticals USA, Inc. $14.9003/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839615143 CMS
Novartis Pharmaceuticals Corporation $19.3203/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813130375 CMS
Allergan, Inc. $13.9003/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792894533 CMS
Avanir Pharmaceuticals, Inc. $16.5003/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801041495 CMS
Amgen Inc. $19.4302/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825449063 CMS
Grifols USA, LLC $15.1002/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846758179 CMS
Allergan, Inc. $15.9702/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792894531 CMS
ACADIA Pharmaceuticals Inc $15.9902/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838013707 CMS
UCB, Inc. $24.0102/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807320151 CMS
AbbVie Inc. $9.4602/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427291 CMS
Acorda Therapeutics, Inc $13.7402/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792555845 CMS
Novartis Pharmaceuticals Corporation $9.4502/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813130379 CMS
Biogen, Inc. $19.9902/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827840885 CMS
Biohaven Pharmaceuticals, Inc. $3.6402/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852582601 CMS
Biohaven Pharmaceuticals, Inc. $16.2202/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852582603 CMS
AbbVie Inc. $15.9502/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427285 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,096.53 112
PY2020 $2,038.04 126
PY2021 $2,835.24 161
PY2022 $2,186.23 139
PY2023 $2,766.18 141
PY2024 $3,332.90 171
PY2025 $3,715.81 194

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $726,645.85 42
PY2024 Principal investigator $728,452.21 38
PY2023 Principal investigator $123,930.54 25
PY2022 Principal investigator $32,868.77 5
PY2021 Principal investigator $25,435.36 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $1,200.00 12/22/2025 Non-covered Recipient Entity
Delricht LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226128496
Principal investigator 1 Novartis Pharmaceuticals Corporation $20.00 12/01/2025 Non-covered Recipient Entity
THE NEUROMEDICAL CENTER
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307709
Principal investigator 1 GENZYME CORPORATION $12,496.00 11/17/2025 Non-covered Recipient Entity
Delricht LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226128479
Principal investigator 1 GENZYME CORPORATION $200.00 11/17/2025 Non-covered Recipient Entity
Delricht LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226128483
Principal investigator 1 GENZYME CORPORATION $11,344.00 11/17/2025 Non-covered Recipient Entity
Delricht LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226128487
Principal investigator 1 Genentech, Inc. $19,226.00 11/17/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596160
Principal investigator 1 Genentech, Inc. $1,000.00 11/05/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596156
Principal investigator 1 Genentech, Inc. $600.00 10/23/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596143
Principal investigator 1 GENZYME CORPORATION $300.00 10/20/2025 Non-covered Recipient Entity
Delricht LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226128472
Principal investigator 1 GENZYME CORPORATION $300.00 10/20/2025 Non-covered Recipient Entity
Delricht LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226128475
Principal investigator 1 Genentech, Inc. $2,508.00 10/15/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596151
Principal investigator 1 Genentech, Inc. $1,000.00 10/09/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596147
Principal investigator 1 GENZYME CORPORATION $10,502.00 09/29/2025 Non-covered Recipient Entity
Delricht LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226128468
Principal investigator 1 GENZYME CORPORATION $69,320.68 09/03/2025 Non-covered Recipient Entity
Delricht LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226128463
Principal investigator 1 Genentech, Inc. $2,899.00 08/21/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596135
Principal investigator 1 Genentech, Inc. $129.00 08/20/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596139
Principal investigator 1 Genentech, Inc. $500.00 08/08/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596131
Principal investigator 1 Novocure GmbH $32,822.99 08/08/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma No dispute reported 06/30/2026 1250868286
Principal investigator 1 GENZYME CORPORATION $2,836.00 07/28/2025 Non-covered Recipient Entity
Delricht LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226128454
Principal investigator 1 GENZYME CORPORATION $33,969.70 07/28/2025 Non-covered Recipient Entity
Delricht LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226128458
Principal investigator 1 Genentech, Inc. $600.00 07/23/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596128
Principal investigator 1 GENZYME CORPORATION $12,159.35 07/02/2025 Non-covered Recipient Entity
Delricht LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226128450
Principal investigator 1 Genentech, Inc. $2,508.00 05/21/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596087
Principal investigator 1 GENZYME CORPORATION $3,100.00 05/19/2025 Non-covered Recipient Entity
Delricht LLC
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226128440
Principal investigator 1 GENZYME CORPORATION $85.00 05/19/2025 Non-covered Recipient Entity
Delricht LLC
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226128445
Principal investigator 1 Genentech, Inc. $300.00 05/13/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596104
Principal investigator 1 Genentech, Inc. $926.00 05/13/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596120
Principal investigator 1 GENZYME CORPORATION $1,000.00 05/12/2025 Non-covered Recipient Entity
Delricht LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226128428
Principal investigator 1 GENZYME CORPORATION $300.00 05/12/2025 Non-covered Recipient Entity
Delricht LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226128432
Principal investigator 1 GENZYME CORPORATION $300.00 05/12/2025 Non-covered Recipient Entity
Delricht LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226128436
Principal investigator 1 Genentech, Inc. $172.00 05/06/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596123
Principal investigator 1 GENZYME CORPORATION $11,300.00 04/14/2025 Non-covered Recipient Entity
Delricht LLC
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226128423
Principal investigator 1 Genentech, Inc. $600.00 04/10/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596116
Principal investigator 1 GENZYME CORPORATION $1,210.34 04/07/2025 Non-covered Recipient Entity
Delricht LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226128420
Principal investigator 1 Genentech, Inc. $2,899.00 04/02/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596107
Principal investigator 1 Genentech, Inc. $9,463.00 03/20/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596111
Principal investigator 1 Novartis Pharmaceuticals Corporation $108,201.64 02/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190309824
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,183.00 02/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190299612
Principal investigator 1 Genentech, Inc. $7,596.00 01/14/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596091
Principal investigator 1 Genentech, Inc. $500.00 01/14/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596095
Principal investigator 1 Genentech, Inc. $600.00 01/14/2025 Non-covered Recipient Entity
DELRICHT LLC DELRICHT RESEARCH
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211596100
Principal investigator 1 Novartis Pharmaceuticals Corporation $354,469.15 01/01/2025 Non-covered Recipient Entity
THE NEUROMEDICAL CENTER
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307711